The information provided here is meant to give you a general idea about each of the medicines listed below. Only the most general side effects are included, so ask your doctor if you need to take any special precautions. Use each of these medicines as recommended by your doctor, or according to the instructions provided. If you have further questions about usage or side effects, contact your doctor.
Medicines for obesity should not be used alone. Rather, they should be part of a comprehensive weight loss program that includes:
Common names include:
These medicines act on your brain to suppress your appetite. Phentermine, phendimetrazine and diethylpropion are only recommended for short-term use (a few weeks).
Possible side effects include:
Common names include: orlistat, available as;
Taken at a dose of 120 milligrams three times a day, Xenical prevents ingested fat from being absorbed by blocking digestive enzymes. About 30% of the fat you eat will remain in your bowels. In some patients the fat is excreted by the body between bowel movements as an oily discharge. It is recommended for long-term use (up to about two years). Orlistat is also available in a 60-mg over-the-counter form, called Alli.
Possible side effects include:
OTC medicines advertised as promoting weight loss are generally considered ineffective. Some have led to serious side effects. Do not use over-the-counter or herbal remedies without talking to your doctor.
To view the latest product safety warnings and recalls, visit the Food and Drug Administration's website.
If you are taking medicines, follow these general guidelines:
Arterburn DE, Crane PK, Veenstra DI. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164:994-1003.
Haddock CK, Poston WSW, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Meta Disord. 2002;26:263-273.
Li Z, Maglione M, et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-546.
Obesity in adults. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated August 16, 2012. Accessed August 28, 2012.
Obesity in children and adolescents. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated July 25, 2012. Accessed August 28, 2012.
Phentermine. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated December 14, 2011. Accessed August 28, 2012.
Prescription medications for the tretment of obesity. National Institute of Diabetes and Digestive and Kidney Diseases. Available at: http://win.niddk.nih.gov/publications/prescription.htm#meds. Accessed August 28, 2012.
Snow V, Barry P, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guidelines from the American College of Physicians. Ann Intern Med. 2005;142:525-531.
Weight loss medications for obesity in adults. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated July 18, 2012. Accessed August 28, 2012.
Wirth A, Krause J. Long-term weight loss with sibutramine: A randomized controlled trial. JAMA. 2001;286:1331-1339.
11/20/2009 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: Pai You Guo, marketed as dietary supplement—recall. US Food and Drug Administration website. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190531.htm. Published November 13, 2009. Accessed November 20, 2009.
1/22/2010 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: Meridia (sibutramine hydrochloride): follow-up to an early communication about an ongoing safety review. US Food and Drug Administration website. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198221.htm. Published January 21, 2010. Accessed January 22, 2010.
5/28/2010 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: Orlistat (marketed as Alli and Xenical): labeling change. US Food and Drug Administration website. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213448.htm. Published March 26, 2010. Accessed March 28, 2010.
9/17/2010 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-917.
10/15/2010 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: US Food and Drug Administration. Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. US Food and Drug Administration website. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm. Published October 8, 2010. Accessed October 15, 2010.
Last reviewed March 2014 by Kim Carmichael, MD
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2012 EBSCO Publishing All rights reserved.
What can we help you find?close ×